|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
N/A |
Shares
Out: |
61,150,000 |
Market
Cap: |
6.68(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$113.49 - $145.93 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
5,163 |
8,867 |
24,764 |
159,606 |
Total Sell Value |
$565,988 |
$1,004,437 |
$3,195,957 |
$22,789,041 |
Total People Sold |
2 |
2 |
12 |
18 |
Total Sell Transactions |
2 |
4 |
20 |
65 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pearce Samantha |
SVP, Head of Europe & Internat |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,210 |
15,369 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,327 |
7,363 |
|
- |
|
Patil Neena M |
EVP & Chief Legal Officer |
|
2024-01-17 |
4 |
D |
$119.13 |
$197,279 |
D/D |
(1,656) |
32,713 |
|
- |
|
Patil Neena M |
EVP & Chief Legal Officer |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,087 |
34,369 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2024-01-17 |
4 |
D |
$119.13 |
$1,458,747 |
D/D |
(12,245) |
402,058 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,545 |
414,303 |
|
- |
|
Smith Mark Douglas |
Director |
|
2023-12-04 |
4 |
S |
$119.27 |
$49,736 |
D/D |
(417) |
6,888 |
|
- |
|
Cook Jennifer E. |
Director |
|
2023-12-04 |
4 |
S |
$119.27 |
$49,736 |
D/D |
(417) |
6,888 |
|
- |
|
Gala Renee D |
President & COO |
|
2023-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
772 |
36,887 |
|
- |
|
Patil Neena M |
EVP & Chief Legal Officer |
|
2023-09-01 |
4 |
AS |
$144.25 |
$216,375 |
D/D |
(1,500) |
29,186 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2023-08-29 |
4 |
S |
$143.47 |
$20,373 |
D/D |
(142) |
5,986 |
|
- |
|
Patil Neena M |
EVP & Chief Legal Officer |
|
2023-08-15 |
4 |
S |
$139.59 |
$104,695 |
D/D |
(750) |
30,686 |
|
- |
|
Sohn Catherine A. |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
14,868 |
|
- |
|
Oriordan Anne |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
12,551 |
|
- |
|
Cook Jennifer E. |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
7,305 |
|
- |
|
Enright Patrick G |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
20,946 |
|
- |
|
Mcsharry Heather Ann |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$185,685 |
D/D |
(1,344) |
16,778 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2023-08-14 |
4 |
S |
$138.16 |
$21,829 |
D/D |
(158) |
6,128 |
|
- |
|
Riedel Norbert G |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
13,705 |
|
- |
|
Gray Peter |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
16,068 |
|
- |
|
Smith Mark Douglas |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
7,305 |
|
- |
|
Winningham Rick E |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
10,444 |
|
- |
|
Okeefe Kenneth W |
Director |
|
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
24,723 |
|
- |
|
Sohn Catherine A. |
Director |
|
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
16,109 |
|
- |
|
Oriordan Anne |
Director |
|
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
13,792 |
|
- |
|
866 Records found
|
|
Page 2 of 35 |
|
|